Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Insight Molecular Diagnostics Inc (IMDX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$2.46-7.17%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IMDX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce cash burn to $6 million per quarter | Management aims to reduce cash burn to $6 million per quarter by late 2026. | Under Pressure | cash burn remains above $6M per quarter in 2H 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not an established earnings compounder, because it remains loss-making and depends on expanding a product that is still awaiting FDA marketing authorization. The long-term thesis is intact, but execution and cash use remain important concerns.
IMDX is valued at a premium to peers, with the valuation case relying on future opportunity rather than current earnings. The expectations gap suggests the market may not fully reflect the company’s weak results and execution risks, though confidence in that assessment is low.
Near term, revenue is likely to remain limited while commercial product sales await FDA authorization; recent revenue was modest, and cash burn was above management’s stated average target. Management continues to prioritize authorization, commercialization, and lower cash burn, but progress so far is mixed, and erratic earnings create risk around the next report.
Over the next year, the key swing factor is whether FDA authorization arrives as management expects and leads to broader commercial adoption. Near term, a guidance cut or further weakening in jobs data could pressure the business outlook, while stronger results and guidance from healthcare peers would support the sector backdrop.
For the 1-to-3-year view, IMDX remains an early-stage, high-risk thesis whose progress depends on regulatory approval, customer adoption, and improved control of cash burn. The thesis is intact, but the evidence is mixed and model confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Insight Molecular Diagnostics has a key agreement with Quest Diagnostics supporting growth. |
| Improving |
| agreement is terminated or materially reduced |
Qualitative: Agreement active (May 2026) May 2026 filing confirms active Specimen Collection Agreement with Quest Diagnostics. No news of termination or reduction. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth stabilizes or improves | A primary condition in Insight Molecular Diagnostics Inc's published investment case. The stated target is revenue decline less than -20% YoY. | Broken | revenue decline exceeds -20% YoY in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.85 → $-0.86 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-07-25 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-07-26 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-07-27 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-07-28 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-07-29 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-07-30 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-07-31 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-01 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-08-02 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-03 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-04 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-05 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-06 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-07 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-08-08 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-09 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-10 | $-0.78 | $7,724,700 | 1 / 4 |
| 2026-08-12 | $-0.78 | $9,866,670 | 1 / 3 |
| 2026-08-13 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-08-14 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-08-15 | $-0.85 | $7,725,000 | 2 / 3 |
| 2026-08-16 | $-0.85 | $7,725,000 | 2 / 3 |
| 2026-08-17 | $-0.85 | $7,725,000 | 2 / 3 |
| 2026-08-18 | $-0.85 | $7,725,000 | 2 / 3 |
| 2026-08-19 | $-0.85 | $7,725,000 | 2 / 4 |
| 2026-08-20 | $-0.87 | $7,133,250 | 2 / 4 |
| 2026-08-21 | $-0.87 | $7,133,250 | 2 / 4 |
| 2026-08-22 | $-0.87 | $7,133,250 | 2 / 4 |
| 2026-08-23 | $-0.87 | $7,133,250 | 2 / 4 |
| 2026-08-24 | $-0.87 | $7,133,250 | 2 / 4 |
| 2026-08-25 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-08-26 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-08-27 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-08-28 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-08-29 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-08-30 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-08-31 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-01 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-02 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-03 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-04 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-05 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-06 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-07 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-08 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-09 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-10 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-11 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-12 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-13 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-14 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-15 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-16 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-17 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-18 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-19 | $-0.85 | $6,706,600 | 3 / 5 |
| 2026-09-20 | $-0.86 | $6,706,600 | 3 / 5 |
| 2026-09-21 | $-0.86 | $6,706,600 | 3 / 5 |
| 2026-09-22 | $-0.86 | $6,706,600 | 3 / 5 |
| 2026-09-23 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-09-24 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-09-25 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-09-26 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-09-27 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-09-28 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-09-29 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-09-30 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-01 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-02 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-03 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-04 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-05 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-06 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-07 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-08 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-09 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-10 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-11 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-12 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-13 | $-0.86 | $6,666,600 | 3 / 5 |
| 2026-10-14 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-15 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-16 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-17 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-18 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-19 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-20 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-21 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-22 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-23 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-24 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-25 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-26 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-27 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-28 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-29 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-30 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-10-31 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-11-01 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-11-02 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-11-03 | $-0.86 | $6,668,860 | 3 / 5 |
| 2026-11-04 | $-0.86 | $6,668,860 | 3 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.